Host-based Immunoassay for Differentiating Bacterial From Viral Infections (Post-marketing Study of ImmunoXpert™ - SPIRIT Study)
Field Study of Host-based Immunoassay for Differentiating Bacterial From Viral Infections (Post-marketing Study of ImmunoXpert™ - SPIRIT Study)
1 other identifier
observational
3,000
1 country
2
Brief Summary
This is a retrospective external field study of a novel in vitro diagnostic (IVD) assay (ImmunoXpert™). The study will involve reviewing the medical charts of about 4500 pediatric patients that were tested using ImmunoXpert™ as part of the routine workup for acute febrile illness. ImmunoXpert™ uses a computer algorithm to combine immunoassay measurements of three host immune proteins (TRAIL, IP-10, and CRP) present in human blood. The test is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection. Statistical analysis will be performed to compare the diagnostic accuracy of ImmunoXpert™ with that of current practice lab testing e.g., WBC, CRP, and PCT (whichever were taken as part of routine care) and clinical suspicion at time of requisition.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2015
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 7, 2015
CompletedFirst Submitted
Initial submission to the registry
March 6, 2017
CompletedFirst Posted
Study publicly available on registry
March 9, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
July 5, 2022
CompletedAugust 4, 2022
August 1, 2022
3.2 years
March 6, 2017
August 2, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
The sensitivity and specificity of a host-response based diagnostics in differentiating between bacterial and viral etiology of patients with an acute febrile disease.
0-7 days after the initiation of symptoms
Secondary Outcomes (1)
The sensitivity and specificity of a host-response based diagnostics in differentiating between infectious and non-infectious disease etiology
0-7 days after the initiation of symptoms
Interventions
Host based immune response test distinguishing viral versus bacterial infection
Eligibility Criteria
1. Patients with an acute bacterial infection 2. Patients with an acute viral infection 3. Patients with an acute co-infection (bacterial and viral) 4. Patients with an undetermined disease etiology
You may qualify if:
- Patients aged 3 month to 18 years that were admitted due to acute febrile illness, and ImmunoDx test was taken as part of their workup.
- The febrile illness should also fulfill the following criteria:
- The patient had a peak temperature ≥38°C (AND)
- Symptoms initiated ≤ 7 days before sampling (AND)
- A retrospective diagnosis of bacterial or viral or mixed infection was anonymously determined by a panel of three independent senior pediatricians.
- The non-infectious disease control group will include:
- A retrospective diagnosis of a non-infectious disease was anonymously determined by a panel of three independent senior pediatricians physicians.
- Patients with a non-infectious disease ( and ImmunoDx test was wrongly taken)
You may not qualify if:
- Samples from patients who had one or more of the following criteria will be excluded from the study:
- Another infection episode during the last 3 weeks before sampling
- Congenital immune deficiency (CID)
- A proven or suspected HIV-1, HBV, HCV infection
- Active hematological malignancy
- Current treatment with immune-suppressive or immune-modulating therapies including without limitations:
- Use of high dose steroids \>1 mg/kg/day prednisone or equivalent in the last two weeks
- Monoclonal antibody administration
- Intravenous immunoglobulin (IVIG)
- Other illnesses that affect life expectancy and/or quality of life
- Suspicion of gastrointestinal infection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Hillel Yaffe Medical center
Hadera, Israel
Bnei Zion medical center
Haifa, 31048, Israel
Related Publications (1)
Klein A, Shapira M, Lipman-Arens S, Bamberger E, Srugo I, Chistyakov I, Stein M. Diagnostic Accuracy of a Real-Time Host-Protein Test for Infection. Pediatrics. 2023 Dec 1;152(6):e2022060441. doi: 10.1542/peds.2022-060441.
PMID: 37916266DERIVED
Biospecimen
Serum and plasma samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 6, 2017
First Posted
March 9, 2017
Study Start
November 7, 2015
Primary Completion
February 1, 2019
Study Completion
July 5, 2022
Last Updated
August 4, 2022
Record last verified: 2022-08
Data Sharing
- IPD Sharing
- Will not share